Current Infectious Disease Reports最新文献

{"title":"Challenges of Antimicrobial Resistance and Stewardship in Solid Organ Transplant Patients.","authors":"Miranda So, Laura Walti","doi":"10.1007/s11908-022-00778-1","DOIUrl":"10.1007/s11908-022-00778-1","url":null,"abstract":"<p><strong>Purpose of review: </strong>Without effective antimicrobials, patients cannot undergo transplant surgery safely or sustain immunosuppressive therapy. This review examines the burden of antimicrobial resistance in solid organ transplant recipients and identifies opportunities for antimicrobial stewardship.</p><p><strong>Recent findings: </strong>Antimicrobial resistance has been identified to be the leading cause of death globally. Multidrug-resistant pathogens are associated with significant morbidity and mortality in transplant recipients. Methicillin-resistant <i>S. aureus</i> affects liver and lung recipients, causing bacteremia, pneumonia, and surgical site infections. Vancomycin-resistant enterococci is a nosocomial pathogen primarily causing bacteremia in liver recipients. Multidrug-resistant Gram-negative pathogens present urgent and serious threats to transplant recipients. Extended-spectrum beta-lactamase-producing <i>E. coli</i> and <i>K. pneumoniae</i> commonly cause bacteremia and intra-abdominal infections in liver and kidney recipients. Carbapenemase-producing Enterobacterales, mainly <i>K. pneumoniae</i>, are responsible for infections early-post transplant in liver, lung, kidney, and heart recipients. <i>P. aeruginosa</i> and <i>A. baumannii</i> continue to be critical threats. While there are new antimicrobial agents targeting resistant pathogens, judicious prescribing is crucial to minimize emerging resistance. The full implications of the COVID-19 global pandemic on antimicrobial resistance in transplant recipients remain to be understood. Currently, there are no established standards on the implementation of antimicrobial stewardship interventions, but strategies that leverage existing antimicrobial stewardship program structure while tailoring to the needs of transplant recipients may help to optimize antimicrobial use.</p><p><strong>Summary: </strong>Clinicians caring for transplant recipients face unique challenges tackling emerging antimcirobial resistance. Coordinated antimicrobial stewardship interventions in collaboration with appropriate expertise in transplant and infectious diseases may mitigate against such threats.</p>","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9055217/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49199889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antifungal Resistance and the Role of New Therapeutic Agents.","authors":"Ashley Logan, Amanda Wolfe, John C Williamson","doi":"10.1007/s11908-022-00782-5","DOIUrl":"10.1007/s11908-022-00782-5","url":null,"abstract":"<p><strong>Purpose of review: </strong>Advances in health care over time have led to an evolution in the epidemiology of invasive fungal infections. There is an increasing concern for antifungal resistance and emergence of less common fungal species for which optimal therapies are not well defined. The purpose of this review is to describe mechanisms of antifungal resistance and to evaluate the modern role of new and investigational antifungals.</p><p><strong>Recent findings: </strong>Isavuconazole and ibrexafungerp represent the two newest antifungal agents. Evidence from in vivo and in vitro studies has been published recently to help define their place in therapy and potential roles in treating resistant fungi. Isavuconazole is a broad-spectrum triazole antifungal with evidence to support its use in invasive aspergillosis and mucormycosis. Its utility in treating voriconazole-resistant <i>Candida</i> should be confirmed with susceptibility testing if available. Ibrexafungerp is an oral glucan synthase inhibitor with little cross-resistance among currently available antifungals, including echinocandins. It is a promising new agent for invasive candidiasis, including azole-resistant <i>Candida</i> species, and in combination therapy with voriconazole for aspergillosis. Multiple antifungals, some with novel mechanisms, are in development, including rezafungin, oteseconazole, olorofim, fosmanogepix, and opelconazole.</p><p><strong>Summary: </strong>Both isavuconazole and ibrexafungerp are welcome additions to the arsenal of antifungals, and the prospect of more antifungal options in the future is encouraging. Such an array of antifungals will be important as antifungal resistance continues to expand alongside evolving medical practices. However, managing resistant fungal infections will grow in complexity as the unique role of each new agent is defined.</p>","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255453/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40489879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"West Nile virus: another emerging arboviral risk for travelers?","authors":"Chinmay Jani,&nbsp;Loukas Kakoullis,&nbsp;Nour Abdallah,&nbsp;Christian Mouchati,&nbsp;Stephanie Page,&nbsp;Robert Colgrove,&nbsp;Lin H Chen","doi":"10.1007/s11908-022-00783-4","DOIUrl":"https://doi.org/10.1007/s11908-022-00783-4","url":null,"abstract":"<p><strong>Purpose of review: </strong>West Nile virus (WNV) is an arbovirus transmitted by mosquitos of the genus <i>Culex</i>. Manifestations of WNV infection range from asymptomatic to devastating neuroinvasive disease leading to flaccid paralysis and death. This review examines WNV epidemiology and ecology, with an emphasis on travel-associated infection.</p><p><strong>Recent findings: </strong>WNV is widespread, including North America and Europe, where its range has expanded in the past decade. Rising temperatures in temperate regions are predicted to lead to an increased abundance of <i>Culex</i> mosquitoes and an increase in their ability to transmit WNV. Although the epidemiologic patterns of WNV appear variable, its geographic distribution most certainly will continue to increase. Travelers are at risk for WNV infection and its complications. Literature review identified 39 cases of documented travel-related WNV disease, the majority of which resulted in adverse outcomes, such as neuroinvasive disease, prolonged recovery period, or death.</p><p><strong>Summary: </strong>The prediction of WNV risk is challenging due to the complex interactions of vector, pathogen, host, and environment. Travelers planning to visit endemic areas should be advised regarding WNV risk and mosquito bite prevention. Evaluation of ill travelers with compatible symptoms should consider the diagnosis of WNV for those visiting in endemic areas as well as for those returning from destinations with known WNV circulation.</p>","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9362398/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40610318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Travel in the Time of COVID: A Review of International Travel Health in a Global Pandemic.","authors":"Gerard T Flaherty,&nbsp;Davidson H Hamer,&nbsp;Lin H Chen","doi":"10.1007/s11908-022-00784-3","DOIUrl":"https://doi.org/10.1007/s11908-022-00784-3","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review critically considers the impact of the COVID-19 pandemic on global travel and the practice of travel medicine, highlights key innovations that have facilitated the resumption of travel, and anticipates how travel medicine providers should prepare for the future of international travel.</p><p><strong>Recent findings: </strong>Since asymptomatic transmission of the virus was first recognized in March 2020, extensive efforts have been made to characterize the pattern and dynamics of SARS-CoV-2 transmission aboard commercial aircraft, cruise ships, rail and bus transport, and in mass gatherings and quarantine facilities. Despite the negative impact of further waves of COVID-19 driven by the more transmissible Omicron variant, rapid increases of international tourist arrivals are occurring and modeling anticipates further growth. Mitigation of spread requires an integrated approach that combines masking, physical distancing, improving ventilation, testing, and quarantine. Vaccines and therapeutics have played a significant role in reopening society and accelerating the resumption of travel and further therapeutic innovation is likely.</p><p><strong>Summary: </strong>COVID-19 is likely to persist as an endemic infection, and surveillance will assume an even more important role. The pandemic has provided an impetus to advance technology for telemedicine, to adopt mobile devices and GPS in contact tracing, and to apply digital applications in research. The future of travel medicine should continue to harness these novel platforms in the clinical, research, and educational arenas.</p>","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40610319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interventions for the Prevention and Treatment of Japanese Encephalitis.","authors":"Rohan Chand Sahu,&nbsp;Teeja Suthar,&nbsp;Anchal Pathak,&nbsp;Keerti Jain","doi":"10.1007/s11908-022-00786-1","DOIUrl":"https://doi.org/10.1007/s11908-022-00786-1","url":null,"abstract":"<p><strong>Purpose of review: </strong>Japanese encephalitis (JE), a clinical indication of JE virus-induced brain inflammation, is the most prevalent cause of viral encephalitis in the world. This review gives a comprehensive update on the epidemiology, clinical features, therapeutic trials and approaches for preventing the spread of JE. It also outlines the different JE vaccines used in various countries and recommendations for administration of JE vaccines.</p><p><strong>Recent findings: </strong>According to the WHO, annual incidence of JE is estimated to be approximately 68,000 cases worldwide. It is widespread across Asia-Pacific, with a potential for worldwide transmission. In endemic locations, JE is believed to affect children below 6 years of age, but in newly affected areas, both adults and children are at risk due to a lack of protective antibodies. Various vaccines have been developed for the prevention of JE and are being administered in endemic countries.</p><p><strong>Summary: </strong>JE is a neuroinvasive disease that causes symptoms ranging from simple fever to severe encephalitis and death. Despite a vast number of clinical trials on various drugs, there is still no complete cure available, and it can only be prevented by adequate vaccination. Various nanotechnological approaches for the prevention and treatment of JE are outlined in this review.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s11908-022-00786-1.</p>","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10367486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in Liver Transplantation for Persons with Human Immunodeficiency Infection.","authors":"Rebecca N Kumar,&nbsp;Valentina Stosor","doi":"10.1007/s11908-022-00776-3","DOIUrl":"https://doi.org/10.1007/s11908-022-00776-3","url":null,"abstract":"<p><strong>Purpose of review: </strong>Advanced liver disease is a leading cause of non-AIDS-related morbidity and mortality in persons with HIV on antiretroviral therapy. As a result, persons with HIV are increasingly seeking liver transplantation.</p><p><strong>Recent findings: </strong>With the availability of direct-acting antiviral hepatitis C therapies, there has been a shift in the indications for liver transplantation in persons with HIV, with non-alcoholic fatty liver disease now the leading indication over hepatitis C infection. Additionally, liver transplant outcomes have improved in persons with HIV-hepatitis C co-infection persons with HIV. Preliminary results of HIV-to-HIV liver transplantation show acceptable results although rates of post-transplant infections and malignancies are areas of concern.</p><p><strong>Summary: </strong>Future studies of liver transplantation in persons with HIV should focus on long-term outcomes, especially in the context of steatohepatitis and co-existing morbidities like diabetes, hyperlipidemia, and cardiovascular disease and other prevalent diseases in an aging population.</p>","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922075/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40307698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Les misérables</i>: a Parallel Between Antimicrobial Resistance and COVID-19 in Underdeveloped and Developing Countries.","authors":"Genesy Pérez Jorge,&nbsp;Isabella Carolina Rodrigues Dos Santos Goes,&nbsp;Marco Tulio Pardini Gontijo","doi":"10.1007/s11908-022-00788-z","DOIUrl":"https://doi.org/10.1007/s11908-022-00788-z","url":null,"abstract":"<p><strong>Purpose of review: </strong>The COVID-19 pandemic has been responsible for more than 6.3 million deaths worldwide. During the pandemic, the indiscriminate use of antibiotics has increased, contributing to the spread of multidrug-resistant bacteria. In this review, we aim to determine the spread and impact of antibiotic treatments in patients with COVID-19, focusing on underdeveloped and developing countries.</p><p><strong>Recent findings: </strong>Meta-analysis revealed that bacterial co-infections and secondary infections are relatively rare in COVID-19 patients, corresponding to less than 20% of hospitalized patients. Even so, most of these patients have received antibiotic treatments.</p><p><strong>Summary: </strong>This review discusses how the COVID-19 pandemic could increase the emergence of multidrug-resistant strains to currently available antibiotics. Initially, we discussed the spread and impact of multidrug resistance of ESKAPE pathogens associated with nosocomial infections and analyzed their risk of secondary infections in patients with COVID-19. Then we highlight three factors related to the spread of resistant bacteria during the current pandemic: overprescription of antibiotics followed by self-medication. Finally, we discussed the lack of availability of diagnostic tests to discriminate the etiologic agent of a disease. All these factors lead to inappropriate use of antibiotics and, therefore, to an increase in the prevalence of resistance, which can have devastating consequences shortly. The data compiled in this study underscore the importance of epidemiological surveillance of hospital isolates to provide new strategies for preventing and controlling infections caused by multidrug-resistant bacteria. In addition, the bibliographic research also highlights the need for an improvement in antibiotic prescribing in the health system.</p>","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10717243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric Infectious Diseases Encountered During Wartime Part II: Infectious Diseases Complications in the Individual Pediatric Patient","authors":"Blake T Cirks, M. Rajnik, K. Madden, Martin Otollini","doi":"10.1007/s11908-021-00771-0","DOIUrl":"https://doi.org/10.1007/s11908-021-00771-0","url":null,"abstract":"","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2021-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43877567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hematologic Parameters of Acute Dengue Fever Versus Other Febrile Illnesses in Ambulatory Returned Travelers","authors":"Dylan C Kain, Dale A. Jechel, Rochelle G. Melvin, F. Jazuli, M. Klowak, J. Mah, Arghavan Omidi, R. Kariyawasam, S. Klowak, A. Boggild","doi":"10.1007/s11908-021-00768-9","DOIUrl":"https://doi.org/10.1007/s11908-021-00768-9","url":null,"abstract":"","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2021-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43936528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Use of Long-Acting Lipoglycopeptides for the Treatment of Serious, Off-label Infections: a Review of the Literature","authors":"Zachary P. Gruss, Tyler Baumeister, Jordan R. Smith","doi":"10.1007/s11908-021-00764-z","DOIUrl":"https://doi.org/10.1007/s11908-021-00764-z","url":null,"abstract":"","PeriodicalId":48839,"journal":{"name":"Current Infectious Disease Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2021-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43048330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}